HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study

Abstract : Background: Crohn's disease (CD) is complicated by perianal fistulas in approximately 20% of patients. Achieving permanent fistula closure remains a challenge for physicians. An association between serum anti-tumor necrosis factor-α concentrations and clinical outcomes in patients with CD has been demonstrated; however, little information is available on serum adalimumab (ADA) concentrations and remission of perianal fistulas in such patients. Aim: To study the relationship between serum ADA concentrations and clinical remission of CD-associated perianal fistulas. Methods: This cross-sectional study of patients with CD-associated perianal fistulas treated with ADA was performed at four French hospitals between December 2013 and March 2018. At the time of each serum ADA concentration measurement, we collected information about the patients and their fistulas. The primary study endpoint was clinical remission of fistulas defined as the absence of drainage (in accordance with Present's criteria), with a PDAI ≤ 4, absence of a seton and assessment of the overall evaluation as favorable by the proctologist at the relevant center. We also assessed fistula healing [defined as being in clinical and radiological (magnetic resonance imaging, MRI) remission] and adverse events. Results: The study cohort comprised 34 patients who underwent 56 evaluations (patients had between one and four evaluations). Fifteen patients had clinical remissions (44%), four of whom had healed fistulas on MRI. Serum ADA concentrations were significantly higher at evaluations in which clinical remission was identified than at evaluations in which it was not [14 (10-16) vs 10 (2-15) μg/mL, P = 0.01]. Serum ADA concentrations were comparable at the times of evaluation of patients with and without healed fistulas [11 (7-14) vs 10 (4-16) μg/mL, P = 0.69]. The adverse event rate did not differ between different serum ADA concentrations. Conclusion: We found a significant association between high serum ADA concentrations and clinical remission of CD-associated perianal fistulas.
Complete list of metadata

https://hal.univ-lorraine.fr/hal-03625177
Contributor : Marcelo de Carvalho Connect in order to contact the contributor
Submitted on : Wednesday, March 30, 2022 - 4:53:49 PM
Last modification on : Tuesday, April 12, 2022 - 9:39:13 AM

Licence


Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Links full text

Identifiers

Citation

Laura Sirmai, Anne-Laure Pelletier, Nathalie Gault, Camille Zallot, Guillaume Bouguen, et al.. Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study. World Journal of Gastroenterology, Baishideng Publishing Group Co. Limited, 2022, 28 (9), pp.961-972. ⟨10.3748/wjg.v28.i9.961⟩. ⟨hal-03625177⟩

Share

Metrics

Record views

19